UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...

Stealth BioTherapeutics received a favorable vote from an FDA advisory committee for elamipretide, aimed at treating Barth ...

Boston-based Upstream Bio debuted on Nasdaq with shares opening 26.5% above its IPO price, valuing the firm at $1.05 billion.

A study in *The New England Journal of Medicine* reported seven blood cancer cases in patients treated with bluebird bio's ...

French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive ...

Indian drugmaker Wockhardt’s today announced that the Subject Expert Committee (SEC) of Indian drug regulator, Central Drugs ...

Roche presented positive two-year data from the RAINBOWFISH study on Evrysdi (risdiplam) for spinal muscular atrophy (SMA) in ...

Shares of French biotech Transgene (tumbled 13.5% to 1.01 euros by late morning after it announced that its randomized Phase ...

The Danish Medicines Council forecasts processing times for treatment evaluations will rise from 19 to 27 weeks by Q1 2025 ...

The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) ...

Turnstone Biologics (Nasdaq: TSBX) is restructuring operations, cutting 60% of its workforce to focus on its lead program, ...

Via a Securities and Exchange Commission (SEC) filing, US biotech Denali Therapeutics (Nasdaq: DNLI) disclosed the scrapping ...